Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Medidata Solutions (NASDAQ:MDSO) Stock Price

News coverage about Medidata Solutions (NASDAQ:MDSO) has trended somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Medidata Solutions earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.919610837415 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the news headlines that may have effected Accern Sentiment’s rankings:

A number of research firms have recently weighed in on MDSO. Royal Bank of Canada assumed coverage on Medidata Solutions in a report on Tuesday, September 19th. They issued a “sector perform” rating and a $82.00 price target on the stock. Dougherty & Co assumed coverage on Medidata Solutions in a report on Thursday, November 2nd. They issued a “neutral” rating on the stock. Zacks Investment Research raised Medidata Solutions from a “sell” rating to a “hold” rating in a report on Wednesday, September 20th. KeyCorp reissued a “buy” rating and issued a $86.00 price target on shares of Medidata Solutions in a report on Sunday, September 17th. Finally, Deutsche Bank assumed coverage on Medidata Solutions in a report on Friday, December 8th. They issued a “buy” rating and a $78.00 price target on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $84.54.

Medidata Solutions (MDSO) traded up $1.06 during midday trading on Monday, hitting $66.90. The stock had a trading volume of 423,300 shares, compared to its average volume of 431,922. The company has a market cap of $3,910.00, a P/E ratio of 95.57, a P/E/G ratio of 3.47 and a beta of 1.69. The company has a current ratio of 1.29, a quick ratio of 3.37 and a debt-to-equity ratio of 0.61. Medidata Solutions has a 52-week low of $47.77 and a 52-week high of $85.92.

Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings data on Thursday, October 26th. The company reported $0.33 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.02. The company had revenue of $140.08 million for the quarter, compared to the consensus estimate of $141.27 million. Medidata Solutions had a return on equity of 11.54% and a net margin of 7.84%. Medidata Solutions’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.28 EPS. research analysts expect that Medidata Solutions will post 0.78 EPS for the current fiscal year.

In related news, CFO Rouven Bergmann sold 2,000 shares of the company’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $65.40, for a total transaction of $130,800.00. Following the completion of the sale, the chief financial officer now directly owns 91,775 shares in the company, valued at approximately $6,002,085. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael I. Otner sold 10,000 shares of the company’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $70.88, for a total value of $708,800.00. Following the sale, the executive vice president now owns 80,674 shares of the company’s stock, valued at $5,718,173.12. The disclosure for this sale can be found here. Insiders sold a total of 239,010 shares of company stock valued at $16,437,036 over the last quarter. Company insiders own 5.80% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Medidata Solutions (NASDAQ:MDSO) Stock Price” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/15/medidata-solutions-mdso-earns-media-sentiment-rating-of-0-17.html.

About Medidata Solutions

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Insider Buying and Selling by Quarter for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply